Zacks Research Estimates Chemours’ FY2026 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Analysts at Zacks Research decreased their FY2026 earnings estimates for shares of Chemours in a report issued on Tuesday, August 18th. Zacks Research analyst Team now expects that the specialty chemicals company will earn $0.83 per share for the year, down from their previous estimate of $0.90. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.88 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.11 EPS, Q4 2027 earnings at $0.61 EPS, FY2027 earnings at $2.05 EPS, Q1 2028 earnings at $0.56 EPS and Q2 2028 earnings at $0.65 EPS.

Chemours (NYSE:CC) last announced its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the prior year, the business earned ($2.54) earnings per share. Chemours’s revenue was down 1.5% compared to the same quarter last year.

A number of other analysts have also recently issued reports on the company. Alembic Global Advisors reissued an “overweight” rating and issued a $30.00 target price on shares of Chemours in a research report on Wednesday, May 13th. Royal Bank Of Canada cut their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. UBS Group reiterated a “neutral” rating and issued a $18.00 price objective (down from $29.00) on shares of Chemours in a research note on Monday, August 10th. Weiss Ratings downgraded Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Finally, BMO Capital Markets lowered their target price on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Chemours has a consensus rating of “Hold” and a consensus target price of $20.10.

Chemours Stock Performance

Shares of CC stock opened at $15.89 on Thursday. The stock’s 50-day moving average is $18.25 and its two-hundred day moving average is $20.04. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. Chemours has a 1 year low of $10.44 and a 1 year high of $28.67. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -8.32 and a beta of 1.43.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 annualized dividend and a yield of 2.2%. Chemours’s dividend payout ratio is currently -18.32%.

Insiders Place Their Bets

In related news, CFO Shane Hostetter bought 3,350 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average price of $14.94 per share, with a total value of $50,049.00. Following the completion of the acquisition, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 8,663 shares of company stock valued at $130,601. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On Chemours

Several institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC purchased a new position in Chemours during the 2nd quarter worth $4,680,000. Empowered Funds LLC purchased a new stake in shares of Chemours in the second quarter valued at about $608,000. Brasada Capital Management LP acquired a new position in shares of Chemours during the second quarter worth about $3,763,000. Jefferies Financial Group Inc. acquired a new position in shares of Chemours during the second quarter worth about $15,996,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Chemours during the second quarter worth about $619,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.